FAP and mesothelioma: A phase I trial of an anti-CD28-costimulated CAR targeting fibroblast activating protein (FAP), a cell-surface antigen highly expressed in epithelial cancers, enrolled three patients with mesothelioma and at least two prior lines of treatment, and delivered therapy intrapleurally.